Molecular differences of angiogenic versus vessel co-opting colorectal cancer liver metastases at single-cell resolution

BACKGROUND: Colorectal cancer liver metastases (CRCLM) are associated with a poor prognosis, reflected by a five-year survival rate of 14%. Anti-angiogenic therapy through anti-VEGF antibody administration is one of the limited therapies available. However, only a subgroup of metastases uses sprouti...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleischer, Johannes Robert, Schmitt, Alexandra Maria, Haas, Gwendolyn, Xu, Xingbo, Zeisberg, Elisabeth Maria, Bohnenberger, Hanibal, Küffer, Stefan, Teuwen, Laure-Anne, Karras, Philipp Johannes, Beißbarth, Tim, Bleckmann, Annalen, Planque, Mélanie, Fendt, Sarah-Maria, Vermeulen, Peter, Ghadimi, Michael, Kalucka, Joanna, De Oliveira, Tiago, Conradi, Lena-Christin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872436/
https://www.ncbi.nlm.nih.gov/pubmed/36691028
http://dx.doi.org/10.1186/s12943-023-01713-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872436/
https://www.ncbi.nlm.nih.gov/pubmed/36691028
http://dx.doi.org/10.1186/s12943-023-01713-1

Ejemplares similares